Developer docs
API playgroundTry for free, no card

Search company profiles

Core Scientific Creations

Full company profile

uuid000h3t8

Namestring
Core Scientific Creations
Legal namestring
Core Scientific Creations Ltd.
Websiteurl
woundclot.org
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKfar Saba, Israel
HQ citystring
Kfar Saba
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hemostatic gauze products, advanced bleeding control, cellulose hemostatic devices, surgical hemostatic devices, trauma wound care
Industry4 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAMAFAF
Wound Care, Bandaging & Consumables (Dressings, Sutures, Staplers)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Medical Devices & Supplies
SECONDARYHLAMANAC
Tissue Engineering & Biomaterial Scaffolds
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Hemostatic Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Hemostatic Medical Devices
TypeOne Time License
Description

Core Scientific Creations generates revenue through the sale of WoundClot hemostatic gauze products. These are medical devices sold to healthcare providers, emergency responders, and military organizations for bleeding control applications. The company sells directly through quote-based procurement for institutional customers.

woundclot.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1WoundClot™ Surgical
Description

Bioabsorbable CE Class III implantable hemostatic effective in management of capillary, venous, and arterial bleeding during surgical procedures

woundclot.org
+3 more records
Core offering1 text field

Core Scientific Creations develops and manufactures the WoundClot™ family of hemostatic gauze products made from cellulose using a patented Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) process. These FDA-cleared and CE Class III certified implantable medical devices are used for rapid bleeding control in surgical, trauma, hemodialysis post-procedure, and veterinary applications. The product converts from a dry flexible gauze to a thick, tenacious 3D gel matrix upon contact with blood, absorbing up to 2,500-3,000% of its weight while activating clotting factors to achieve hemostasis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • WoundClot use shortened bleeding time significantly - mean venous bleeding time decreased by 3.99 minutes and mean arterial bleeding time by 6.38 minutes compared to cotton gauze (p < 0.001) in hemodialysis AVF decannulation study
+3 more records
Product overview1 text field

Core Scientific Creations develops the WoundClot™ family of hemostatic gauze products, which are FDA-cleared medical devices made from cellulose using a patented Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) process. The portfolio includes four product lines: WoundClot™ Surgical (a CE Class III implantable hemostatic for surgical procedures), WoundClot™ Trauma (for pre-hospital emergency responders managing traumatic wounds), WoundClot™ Twin Pack (designed specifically for post-hemodialysis bleeding control), and WoundClot™ Veterinarian (for veterinary applications). All products share the same core technology platform—a cellulose-based gauze that converts to a 3D gel matrix upon contact with blood, achieving hemostasis through absorption, adhesion, aggregation, and activation of clotting factors. The technology absorbs up to 2,500-3,000% of its weight in blood and remains actively absorbent for up to 24 hours.

Product and service4 records
1WoundClot™ Surgical
CategoryHemostatic Medical Devices
Description

A bioabsorbable CE Class III Implantable hemostatic device effective in the management of capillary, venous, and arterial bleeding during surgical procedures. Uses Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) technology intended for trauma surgery, cardiovascular surgery, plastic surgery, orthopedic surgery, OB/GYN, EENT, interventional medicine, and other surgical applications.

2WoundClot™ Trauma
CategoryHemostatic Medical Devices
Description

A next-generation hemostatic gauze intended for bleeding control of traumatic wounds, including moderate to severe bleeding. Designed for use by trained emergency responders, military personnel, law enforcement, and EMS in pre-hospital and tactical settings.

3WoundClot™ Twin Pack
CategoryHemostatic Medical Devices
Description

A twin-pack configuration featuring 2 pieces of WoundClot™ hemostatic gauze designed for post hemodialysis bleeding control at arteriovenous fistula access sites or for post-procedure bleeding in interventional medicine.

4WoundClot™ Veterinarian
CategoryHemostatic Medical Devices
Description

A next-generation hemostatic gauze indicated for the control of mild, moderate, and severe bleeding in veterinary applications. Available in sizes including 10cm x 10cm, 8cm x 20cm, and 8cm x 100cm for veterinary surgical procedures and animal trauma care.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Ethicon, a J&J subsidiary, makes Surgicel (oxidized regenerated cellulose) and other surgical hemostats widely used in operating rooms. Surgicel is the established ORC hemostatic that WoundClot Surgical directly differentiates against with its NONRCS structure.

TypeDirect peer
Description

BioCer develops Chitogauze and other chitosan-based hemostatic products serving military, EMS, and surgical markets. Smaller specialty competitor with overlapping product mechanism and customer overlap to WoundClot.

TypeDirect peer
Description

Z-Medica, now part of Teleflex, manufactures QuikClot Combat Gauze, the standard-issue military hemostatic and the leading kaolin-based gauze competitor to WoundClot. It is the closest direct peer in product category, customer base (military, EMS, hospitals), and clinical positioning.

TypeBroad incumbent
Description

Baxter manufactures Floseal, Tisseel, and other surgical hemostats/sealants used in operating rooms globally. A broad incumbent in the surgical hemostasis space that overlaps with WoundClot Surgical in clinical use cases, though Baxter's products are protein/sealant-based rather than gauze-based.

TypeDirect peer
Description

Advanced Medical Solutions (AMS) is a UK-based wound care and surgical adhesives specialist that produces hemostatic products (e.g., ActivHeal, LiquiBand) competing with WoundClot in surgical and emergency wound management across European and global markets.

TypeEmerging player
Description

Hemostasis Today (or comparable specialty hemostatic start-ups such as Cresilon/Hemostatic Gel) are emerging competitors developing next-generation hemostatic technologies for trauma and surgical use. They represent the emerging-technology frontier that WoundClot competes against for the next wave of hospital and military procurement.

TypeBroad incumbent
Description

BD produces a broad surgical and hemostasis portfolio through its BD Interventional and Medical Surgical segments, supplying hospitals and EMS with hemostatic devices, surgical supplies, and adjacent wound-care products. Overlaps with WoundClot in hospital and surgical procurement channels.

TypeBroad incumbent
Description

Integra LifeSciences manufactures a broad portfolio of surgical and wound-care products including regenerative wound matrices (Integra Dermal Regeneration Template) that overlap with WoundClot in surgical hemostasis and advanced wound management, though via different technology platforms.

TypeDirect peer
Description

Tricol Biomedical produces HemCon chitosan-based hemostatic dressings and other chitosan wound-care products that compete with WoundClot in trauma and surgical hemostasis. Comparable in product mechanism and target customer (military, EMS, hospitals).

TypeDirect peer
Description

Medtrade Products manufactures Celox, a chitosan-based hemostatic gauze directly competing with WoundClot in trauma, EMS, and military channels. Celox uses a single mechanism (chitosan), making it a direct functional comparator to WoundClot's multi-mechanism NONRCS gauze.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Core Scientific Creations

Hemostatic Medical Deviceswoundclot.org

Core Scientific Creations firmographics

Firmographics
Name
Core Scientific Creations
Legal name
Core Scientific Creations Ltd.
Website
https://woundclot.org
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Core Scientific Creations industry classification

Industry
Product category
Hemostatic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAMAFAF
Wound Care, Bandaging & Consumables (Dressings, Sutures, Staplers)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Medical Devices & Supplies
SECONDARYHLAMANAC
Tissue Engineering & Biomaterial Scaffolds
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Hemostatic gauze products
  • Advanced bleeding control
  • Cellulose hemostatic devices
  • Surgical hemostatic devices
  • Trauma wound care

Where Core Scientific Creations is headquartered

Location

Headquarters

HQ city
Kfar Saba
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Core Scientific Creations business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Hemostatic Medical Devices: Core Scientific Creations generates revenue through the sale of WoundClot hemostatic gauze products. These are medical devices sold to healthcare providers, emergency responders, and military organizations for bleeding control applications. The company sells directly through quote-based procurement for institutional customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core Scientific Creations product offering

Product offering

Core offering

Core Scientific Creations develops and manufactures the WoundClot™ family of hemostatic gauze products made from cellulose using a patented Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) process. These FDA-cleared and CE Class III certified implantable medical devices are used for rapid bleeding control in surgical, trauma, hemodialysis post-procedure, and veterinary applications. The product converts from a dry flexible gauze to a thick, tenacious 3D gel matrix upon contact with blood, absorbing up to 2,500-3,000% of its weight while activating clotting factors to achieve hemostasis.

Product overview

Core Scientific Creations develops the WoundClot™ family of hemostatic gauze products, which are FDA-cleared medical devices made from cellulose using a patented Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) process. The portfolio includes four product lines: WoundClot™ Surgical (a CE Class III implantable hemostatic for surgical procedures), WoundClot™ Trauma (for pre-hospital emergency responders managing traumatic wounds), WoundClot™ Twin Pack (designed specifically for post-hemodialysis bleeding control), and WoundClot™ Veterinarian (for veterinary applications). All products share the same core technology platform—a cellulose-based gauze that converts to a 3D gel matrix upon contact with blood, achieving hemostasis through absorption, adhesion, aggregation, and activation of clotting factors. The technology absorbs up to 2,500-3,000% of its weight in blood and remains actively absorbent for up to 24 hours.

Differentiator

Problem solved

Functional benefit

Brands

  • WoundClot™ Surgical: Bioabsorbable CE Class III implantable hemostatic effective in management of capillary, venous, and arterial bleeding during surgical procedures
  • WoundClot™ Trauma
  • WoundClot™ Twin Pack
  • WoundClot™ Veterinarian

Products and services

  • WoundClot™ Surgical A bioabsorbable CE Class III Implantable hemostatic device effective in the management of capillary, venous, and arterial bleeding during surgical procedures. Uses Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) technology intended for trauma surgery, cardiovascular surgery, plastic surgery, orthopedic surgery, OB/GYN, EENT, interventional medicine, and other surgical applications.
  • WoundClot™ Trauma A next-generation hemostatic gauze intended for bleeding control of traumatic wounds, including moderate to severe bleeding. Designed for use by trained emergency responders, military personnel, law enforcement, and EMS in pre-hospital and tactical settings.
  • WoundClot™ Twin Pack A twin-pack configuration featuring 2 pieces of WoundClot™ hemostatic gauze designed for post hemodialysis bleeding control at arteriovenous fistula access sites or for post-procedure bleeding in interventional medicine.
  • WoundClot™ Veterinarian A next-generation hemostatic gauze indicated for the control of mild, moderate, and severe bleeding in veterinary applications. Available in sizes including 10cm x 10cm, 8cm x 20cm, and 8cm x 100cm for veterinary surgical procedures and animal trauma care.

Quantifiable outcome

  • WoundClot use shortened bleeding time significantly - mean venous bleeding time decreased by 3.99 minutes and mean arterial bleeding time by 6.38 minutes compared to cotton gauze (p < 0.001) in hemodialysis AVF decannulation study
  • +3 more outcomes

Companies that use Core Scientific Creations

Customer profile

Segments6 records

Ideal customer profiles6 records

Core Scientific Creations technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Core Scientific Creations partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Core Scientific Creations competitors and assessment

Company assessment

Broad incumbents

  • Ethicon (Johnson & Johnson): Ethicon, a J&J subsidiary, makes Surgicel (oxidized regenerated cellulose) and other surgical hemostats widely used in operating rooms. Surgicel is the established ORC hemostatic that WoundClot Surgical directly differentiates against with its NONRCS structure.
  • Baxter International: Baxter manufactures Floseal, Tisseel, and other surgical hemostats/sealants used in operating rooms globally. A broad incumbent in the surgical hemostasis space that overlaps with WoundClot Surgical in clinical use cases, though Baxter's products are protein/sealant-based rather than gauze-based.
  • Becton Dickinson (BD): BD produces a broad surgical and hemostasis portfolio through its BD Interventional and Medical Surgical segments, supplying hospitals and EMS with hemostatic devices, surgical supplies, and adjacent wound-care products. Overlaps with WoundClot in hospital and surgical procurement channels.
  • Integra LifeSciences: Integra LifeSciences manufactures a broad portfolio of surgical and wound-care products including regenerative wound matrices (Integra Dermal Regeneration Template) that overlap with WoundClot in surgical hemostasis and advanced wound management, though via different technology platforms.

Direct peers

  • BioCer Entwicklungs-GmbH: BioCer develops Chitogauze and other chitosan-based hemostatic products serving military, EMS, and surgical markets. Smaller specialty competitor with overlapping product mechanism and customer overlap to WoundClot.
  • Z-Medica (Teleflex): Z-Medica, now part of Teleflex, manufactures QuikClot Combat Gauze, the standard-issue military hemostatic and the leading kaolin-based gauze competitor to WoundClot. It is the closest direct peer in product category, customer base (military, EMS, hospitals), and clinical positioning.
  • Advanced Medical Solutions: Advanced Medical Solutions (AMS) is a UK-based wound care and surgical adhesives specialist that produces hemostatic products (e.g., ActivHeal, LiquiBand) competing with WoundClot in surgical and emergency wound management across European and global markets.
  • Tricol Biomedical (HemCon): Tricol Biomedical produces HemCon chitosan-based hemostatic dressings and other chitosan wound-care products that compete with WoundClot in trauma and surgical hemostasis. Comparable in product mechanism and target customer (military, EMS, hospitals).
  • Medtrade Products: Medtrade Products manufactures Celox, a chitosan-based hemostatic gauze directly competing with WoundClot in trauma, EMS, and military channels. Celox uses a single mechanism (chitosan), making it a direct functional comparator to WoundClot's multi-mechanism NONRCS gauze.

Emerging players

  • Hemostasis Today: Hemostasis Today (or comparable specialty hemostatic start-ups such as Cresilon/Hemostatic Gel) are emerging competitors developing next-generation hemostatic technologies for trauma and surgical use. They represent the emerging-technology frontier that WoundClot competes against for the next wave of hospital and military procurement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Core Scientific Creations compliance and trust

Trust signal

Compliance2 records

Core Scientific Creations financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Core Scientific Creations leadership team

Management profile

Number of profiles

Core Scientific Creations funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Core Scientific Creations M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Core Scientific Creations

What does Core Scientific Creations do?

Core Scientific Creations develops and manufactures the WoundClot™ family of hemostatic gauze products made from cellulose using a patented Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) process. These FDA-cleared and CE Class III certified implantable medical devices are used for rapid bleeding control in surgical, trauma, hemodialysis post-procedure, and veterinary applications. The product converts from a dry flexible gauze to a thick, tenacious 3D gel matrix upon contact with blood, absorbing up to 2,500-3,000% of its weight while activating clotting factors to achieve hemostasis.

Is Core Scientific Creations a public or private company?

Core Scientific Creations is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Core Scientific Creations founded?

Core Scientific Creations was founded in 2012. It employs 11 to 50 people.

Where is Core Scientific Creations based?

Core Scientific Creations is headquartered in Kfar Saba, Israel, in the Middle East region.

How does Core Scientific Creations make money?

One revenue line is on record: hemostatic Medical Devices.

Who are Core Scientific Creations's main competitors?

Broad incumbents on record are Ethicon (Johnson & Johnson), Baxter International, Becton Dickinson (BD) and Integra LifeSciences. Direct peers are BioCer Entwicklungs-GmbH, Z-Medica (Teleflex), Advanced Medical Solutions, Tricol Biomedical (HemCon) and Medtrade Products. Hemostasis Today is listed as an emerging player.

Does Core Scientific Creations have an API?

No public API is recorded for Core Scientific Creations.

What industry is Core Scientific Creations in?

Core Scientific Creations's product category is Hemostatic Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales